| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GPR44 |
| Uniprot No | Q9Y5Y4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-395aa |
| 氨基酸序列 | MSANATLKPLCPILEQMSRLQSHSNTSIRYIDHAAVLLHGLASLLGLVENGVILFVVGCRMRQTVVTTWVLHLALSDLLASASLPFFTYFLAVGHSWELGTTFCKLHSSIFFLNMFASGFLLSAISLDRCLQVVRPVWAQNHRTVAAAHKVCLVLWALAVLNTVPYFVFRDTISRLDGRIMCYYNVLLLNPGPDRDATCNSRQVALAVSKFLLAFLVPLAIIASSHAAVSLRLQHRGRRRPGRFVRLVAAVVAAFALCWGPYHVFSLLEARAHANPGLRPLVWRGLPFVTSLAFFNSVANPVLYVLTCPDMLRKLRRSLRTVLESVLVDDSELGGAGSSRRRRTSSTARSASPLALCSRPEEPRGPARLLGWLLGSCAASPQTGPLNRALSSTSS |
| 预测分子量 | 43,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GPR44(CRTH2)重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells via CRTH2*
**作者**：Hirai H. et al.
**摘要**：本研究首次克隆并表达了CRTH2(GPR44)重组蛋白，证明其作为前列腺素D2(PGD2)受体，介导Th2细胞的趋化作用，为过敏反应机制提供了关键证据。
2. **文献名称**：*CRTH2. a G protein-coupled receptor for prostaglandin D2. is specifically expressed in T helper type 2 cells*
**作者**：Nagata K. et al.
**摘要**：作者通过重组CRTH2蛋白的功能分析，揭示了其在Th2细胞中的特异性表达及信号传导途径，证实PGD2通过该受体调控Th2相关免疫反应。
3. **文献名称**：*Structural basis of prostaglandin D2 binding to CRTH2 receptor*
**作者**：Sugimoto H. et al.
**摘要**：利用重组CRTH2蛋白的晶体结构解析，阐明了PGD2与其结合的关键结构域，为靶向该受体的药物设计(如抗过敏疗法)提供了结构基础。
*注*：若需获取全文或补充年份/期刊信息，可通过PubMed或Sci-Hub输入标题进一步检索。
GPR44 (G protein-coupled receptor 44), also known as CRTH2 (Chemoattractant Receptor-Homologous Molecule expressed on Th2 cells), is a class A G protein-coupled receptor (GPCR) primarily involved in inflammatory and immune responses. It was first identified in 2001 as a receptor for prostaglandin D2 (PGD2), a lipid mediator derived from arachidonic acid. Structurally, GPR44 features seven transmembrane domains characteristic of GPCRs and is expressed on immune cells such as Th2 lymphocytes, eosinophils, and basophils. Its activation by PGD2 triggers intracellular signaling via Gi/o proteins, leading to reduced cAMP levels, calcium mobilization, and chemotaxis, thereby amplifying allergic inflammation.
Research has linked GPR44 to pathologies including asthma, allergic rhinitis, atopic dermatitis, and certain cancers. Its role in Th2-mediated inflammation makes it a therapeutic target for allergic diseases. Recombinant GPR44 protein—produced through heterologous expression systems like mammalian or insect cells—retains the receptor’s native conformation and functionality, enabling biochemical and pharmacological studies. Purification typically involves affinity chromatography with tags like His or FLAG. This recombinant protein is instrumental in drug discovery, particularly for screening antagonists to block PGD2-GPR44 interactions. Several small-molecule antagonists (e.g., fevipiprant) have entered clinical trials for asthma treatment. Additionally, it aids in structural studies to elucidate ligand-binding mechanisms and develop targeted therapies. Despite progress, challenges remain in optimizing receptor stability and understanding its dual pro-/anti-inflammatory roles in different disease contexts.
×
